Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1994-2002

  Levesque, Marc C ^a   Hobbs, Maurine R ^b   Anstey, Nicholas M ^c   Vaughn, Trisha N ^a   Chancellor, Jennifer A ^a   Pole, Ann ^b   Perkins, Douglas J ^a   Misukonis, Mary A ^a   Chanock, Stephen J ^d   Granger, Donald L ^b   Weinberg, J Brice ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE;

ARTICLE; CAUCASIAN; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; NEGRO; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; TANZANIA;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; CHILD; CHILD, PRESCHOOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; INFANT; MALARIA, CEREBRAL; MALARIA, FALCIPARUM; MICROSATELLITE REPEATS; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); SEVERITY OF ILLNESS INDEX; TANZANIA;

EID: 0032758650     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315140     Document Type: Article

References (23)

1. 1. World Health Organization. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990;84(suppl 2):1-65.
2. 2. Hill AV. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998;16:593-617.
3. 3. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide related antimicrobial activity. J Clin Invest 1997;99:2818-25.
4. 4. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997;100:2417-23.
5. 5. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994;63:175-95.
6. 6. Weinberg JB. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med 1998;4: 557-91.
7. 7. Anstey NM, Weinberg JB, Granger DL. Nitric oxide and nitric oxide synthase type 2 in severe malaria. In: Fang F, ed. Nitric oxide and infection. New York: Plenum Publishing, 1999:311-41.
8. + T cells. J Exp Med 1994;180:353-8.
9. 9. Taylor-Robinson AW, Phillips RS, Severn A, Moncada S, Liew FY. The role of TH1 and TH2 cells in a rodent malaria infection. Science 1993;260: 1931-4.
10. 10. Anstey NM. Weinberg JB, Hassanali MY, et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 1996;184:557-67.
11. 11. Taylor BS, de Vera ME, Ganster RW, et al. Multiple NF-κB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998;273:15148-56.
12. 12. Chartrain NA, Geller DA, Koty PP, et al. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J Biol Chem 1994;269:6765-72.
13. 13. Kun JF, Mordmuller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria [letter]. Lancet 1998;351:265-6.
14. 14. Burgner D, Xu WM, Rockett K, Gravenor M, Charles IG, Hill AV, Kwiatkowski D. Inducible nitric oxide synthase polymorphism and fatalcerebral malaria. Lancet 1998;352:1193-4.
15. 15. Xu W, Liu L, Emson PC, Harrington CR, Charles IG. Evolution of a homopurine-homopyrimkline pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. Gene 1997;204:165-70.
16. 16. Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989;71:441-59.
17. 17. Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998;102:2146-55.
18. 18. Spitsin SV, Koprowski H, Michaels FH. Characterization and functional analysis of the human inducible nitric oxide synthase gene promoter. Mol Med 1996;2:226-35.
19. 19. Nunokawa Y, Ishida N, Tanaka S. Promoter analysis of human inducible nitric oxide synthase gene associated with cardiovascular homeostasis. Biochem Biophys Res Commun 1994;200:802-7.
20. 20. St Clair EW, Wilkinson WE, Lang T, et al. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. J Exp Med 1996;184:1173-8.
21. 21. Warpeha KM, Xu W, Liu L, Charles IG, Patterson CC. Ah-Fat F, Harding S, et al. Genotyping and functional analysis of a polymorphic (CCTTT)n repeat of NOS2A in diabetic retinopathy. FASEB J 1993;13:1825-32.
22. 22. Fernandez-Reyes D, Craig AG, Kyes SA, et al. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. Hum Mol Genet 1997;6:1357-60.
23. 23. Bellamy R, Kwiatkowski D, Hill AVS. Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a west African population. Trans R Soc Trop Med Hyg 1998;92:312-6.